International guidelines
Integrates relevant genotypes into higher level CPIC, DPWG and PharmGKB evidence recommendations.
Pharmacogenomics in neurology and psychiatry
Genetic information to guide therapeutic choices.
Pharmacogenomics can support decisions in different areas of medicine. NeoFarma Neurologia has a specific focus on medications used in neurology and psychiatry, always integrated into the clinical context.
The result supports the professional decision and must be interpreted in conjunction with the patient's clinical picture, medications in use and other factors.
- Scope
- Neurology and psychiatry
- Sample
- Mouth swab
- References
- CPIC, DPWG and PharmGKB
- Deadline
- Up to 10 calendar days*
What the test adds
From variant to clinical recommendation.
The report brings together the pharmacogenomic profile and available evidence to support medication selection, dose adjustment and monitoring.
Genes and therapeutic classes
Evaluates metabolizing enzymes, transporters and targets associated with neurology and psychiatry drugs.
Expert discussion
The team supports professionals and institutions in interpreting and incorporating findings into the therapeutic plan.
When to consider
Cases where drug response needs more context.
The indication must consider therapeutic history, response, adverse events, interactions and clinical objectives.
01
Partial response or adverse effects
Depressive or anxiety disorders with cycles of trial and error.
02
Complex therapeutic adjustment
ADHD, ASD, epilepsy or combinations with incomplete response.
03
Movement and pain
Use of antipsychotics, VMAT-2 modulators, anticonvulsants or opioids.
04
Polypharmacy
Elderly people, sensitive populations and hospital programs that require greater attention to interactions.
Clinical scope
Therapeutic classes evaluated.
The selection of genes and drugs follows the technical scope of the examination and the main clinical pharmacogenomics guidelines.
Swipe to consult
| Class | Subcategory | Examples of pharmaceuticals | Core genes |
|---|---|---|---|
| Antidepressants | SSRI and SNRI | Sertraline, escitalopram, citalopram, venlafaxine, vortioxetine | CYP2C19, CYP2D6, CYP2B6 |
| Antidepressants | Tricyclics | Amitriptyline, nortriptyline, clomipramine, imipramine, desipramine | CYP2D6, CYP2C19 |
| Antipsychotics | First and second generation | Aripiprazole, risperidone, haloperidol, ziprasidone, quetiapine, pimozide | CYP2D6, CYP3A4 |
| Motion control | Anticonvulsants and VMAT-2 | Phenytoin, tetrabenazine, deutetrabenazine | CYP2C9, CYP2D6 |
| Analgesia and pain | Opioids and adjuvants | Codeine, tramadol, hydrocodone, oxycodone | CYP2D6, CYP2C9 |
| Specific modulators | Benzodiazepines and ADHD | Diazepam, clobazam, atomoxetine and adjuvants | CYP2C19, CYP2D6 |
Informed choice
What differentiates an expanded clinical analysis?
NeoFarma Neurologia combines genetic data with guidelines, curation and support so that the result is incorporated into routine care.
Swipe to compare
| Appearance | NeoFarma Neurology | Basic test | No pharmacogenomics |
|---|---|---|---|
| Genes | CYPs, transporters and relevant targets | Reduced panel of CYPs | Not evaluated |
| Guidelines | CPIC, DPWG and PharmGKB | Selected references | Not applicable |
| Recommendation | Dose, alternative, monitoring and interactions | Scope-limited guidance | Clinical fit without genetic data |
| Update | Review when new evidence changes the recommendation | No scheduled reevaluation | Not applicable |
Update NeoFarma Neurologia
Evidence evolves. The interpretation too.
CPIC and DPWG guidelines, regulatory information and relevant publications are monitored. Changes that impact the recommendation undergo clinical review before an update.
- 01Changes in evidence levels and security alerts are identified.
- 02The clinical team reviews the relevance to the result already issued.
- 03When applicable, the guidance is updated without new sample collection.
Assisted flow
From request to therapeutic plan.
A process designed to integrate pharmacogenomics into clinical routine.
-
01
Clinical request
The team confirms the indication, therapeutic history and medications in use.
-
02
Simplified sample collection
The mouth swab kit comes with a medication checklist and instructions.
-
03
Sequencing and curation
Pharmacogenomic genes undergo technical analysis and clinical review.
-
04
Practical recommendations
The report brings together dose, alternatives and monitoring alerts.
-
05
Discussion with experts
The team supports the incorporation of findings into the therapeutic plan.
* Deadline counted after receipt of the sample and necessary information.
Clinical deliverable
A report prepared for the decision.
The executive summary highlights the medicines with pharmacogenomic recommendations and presents the suggested procedures in accordance with the applicable guidelines.
- Predicted metabolizing profile
- Dose adjustments and alternatives when indicated
- Interactions and monitoring points
- CPIC and DPWG References
Real excerpt from the NeoReport demonstration environment, cut without personal data.
Frequently asked questions
About NeoFarma Neurologia.
What is the role of pharmacogenomics in neurology and psychiatry?+
It adds information about how genetic variants can influence metabolism, response or risk of adverse events. This information is integrated into the clinical assessment.
Which classes receive recommendations?+
The scope includes antidepressants, antipsychotics, anticonvulsants, VMAT-2 modulators, opioids, benzodiazepines and atomoxetine, among other drugs defined by the test.
For which patients can it be considered?+
It can be useful in the face of partial response, adverse events, polypharmacy or the need to structure pharmacogenomic protocols, always in accordance with professional assessment.
Is it necessary to suspend medication before sample collection?+
No. DNA is obtained by mouth swab. The medications in use must be informed to contextualize the interpretation, without changing the treatment without medical guidance.
What is the deadline for the result?+
The report is delivered within 10 calendar days after receiving the sample and the necessary information.
Is it necessary to repeat the test in the future?+
DNA does not change. When new evidence impacts the recommendation, the result can be reassessed without a new sample collection, according to the service's criteria.
Clinical integration
Bring pharmacogenomics into routine care.
Talk to the team about cases, institutional protocols and demonstrative reports.
Catalog information
Technical data of NeoFarma Neurology
Pharmacogenomics applied to neurology and psychiatry medicines.
- Applications
- Pharmacogenomics
- Accepted samples
- peripheral blood, Mouth swab (preferred), DNA extraído
- Estimated deadline
- 10 calendar days, contados após the complete documentation.
- Methodology
- Pharmacogenomic gene sequencing, clinical curation and interpretation according to CPIC, DPWG and PharmGKB.
- Analytical scope
- Metabolizing enzymes, transporters and targets associated with neurology and psychiatry drugs, according to the current technical scope.
- Medical request
- Required
Requirements
Clinical request, therapeutic history, list of medications in use, sample and necessary information.
Limitations
The result is an additional layer of information and does not replace clinical decision-making. Treatment should not be changed without medical advice.
